Biophysical characterization of the phase separation of TDP-43 devoid of the C-terminal domain.

Electrostatics LLPS Liquid–liquid phase separation Liquid–solid phase separation Motor neuron diseases RNA-binding proteins Self-assembly

Journal

Cellular & molecular biology letters
ISSN: 1689-1392
Titre abrégé: Cell Mol Biol Lett
Pays: England
ID NLM: 9607427

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 18 12 2023
accepted: 25 06 2024
medline: 13 7 2024
pubmed: 13 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-TDP), amyotrophic lateral sclerosis (ALS) and limbic-predominant age-related TDP-43 encephalopathy (LATE) are associated with deposition of cytoplasmic inclusions of TAR DNA-binding protein 43 (TDP-43) in neurons. One complexity of this process lies in the ability of TDP-43 to form liquid-phase membraneless organelles in cells. Previous work has shown that the recombinant, purified, prion-like domain (PrLD) forms liquid droplets in vitro, but the behaviour of the complementary fragment is uncertain. We have purified such a construct without the PrLD (PrLD-less TDP-43) and have induced its phase separation using a solution-jump method and an array of biophysical techniques to study the morphology, state of matter and structure of the TDP-43 assemblies. The fluorescent TMR-labelled protein construct, imaged using confocal fluorescence, formed rapidly (< 1 min) round, homogeneous and 0.5-1.0 µm wide assemblies which then coalesced into larger, yet round, species. When labelled with AlexaFluor488, they initially exhibited fluorescence recovery after photobleaching (FRAP), showing a liquid behaviour distinct from full-length TDP-43 and similar to PrLD. The protein molecules did not undergo major structural changes, as determined with circular dichroism and intrinsic fluorescence spectroscopies. This process had a pH and salt dependence distinct from those of full-length TDP-43 and its PrLD, which can be rationalized on the grounds of electrostatic forces. Similarly to PrLD, PrLD-less TDP-43 forms liquid droplets in vitro through liquid-liquid phase separation (LLPS), unlike the full-length protein that rather undergoes liquid-solid phase separation (LSPS). These results offer a rationale of the complex electrostatic forces governing phase separation of full-length TDP-43 and its fragments. On the one hand, PrLD-less TDP-43 has a low pI and oppositively charged domains, and LLPS is inhibited by salts, which attenuate inter-domain electrostatic attractions. On the other hand, PrLD is positively charged due to a high isoionic point (pI) and LLPS is therefore promoted by salts and pH increases as they both reduce electrostatic repulsions. By contrast, full-length TDP-43 undergoes LSPS most favourably at its pI, with positive and negative salt dependences at lower and higher pH, respectively, depending on whether repulsive or attractive forces dominate, respectively.

Sections du résumé

BACKGROUND BACKGROUND
Frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-TDP), amyotrophic lateral sclerosis (ALS) and limbic-predominant age-related TDP-43 encephalopathy (LATE) are associated with deposition of cytoplasmic inclusions of TAR DNA-binding protein 43 (TDP-43) in neurons. One complexity of this process lies in the ability of TDP-43 to form liquid-phase membraneless organelles in cells. Previous work has shown that the recombinant, purified, prion-like domain (PrLD) forms liquid droplets in vitro, but the behaviour of the complementary fragment is uncertain.
METHODS METHODS
We have purified such a construct without the PrLD (PrLD-less TDP-43) and have induced its phase separation using a solution-jump method and an array of biophysical techniques to study the morphology, state of matter and structure of the TDP-43 assemblies.
RESULTS RESULTS
The fluorescent TMR-labelled protein construct, imaged using confocal fluorescence, formed rapidly (< 1 min) round, homogeneous and 0.5-1.0 µm wide assemblies which then coalesced into larger, yet round, species. When labelled with AlexaFluor488, they initially exhibited fluorescence recovery after photobleaching (FRAP), showing a liquid behaviour distinct from full-length TDP-43 and similar to PrLD. The protein molecules did not undergo major structural changes, as determined with circular dichroism and intrinsic fluorescence spectroscopies. This process had a pH and salt dependence distinct from those of full-length TDP-43 and its PrLD, which can be rationalized on the grounds of electrostatic forces.
CONCLUSIONS CONCLUSIONS
Similarly to PrLD, PrLD-less TDP-43 forms liquid droplets in vitro through liquid-liquid phase separation (LLPS), unlike the full-length protein that rather undergoes liquid-solid phase separation (LSPS). These results offer a rationale of the complex electrostatic forces governing phase separation of full-length TDP-43 and its fragments. On the one hand, PrLD-less TDP-43 has a low pI and oppositively charged domains, and LLPS is inhibited by salts, which attenuate inter-domain electrostatic attractions. On the other hand, PrLD is positively charged due to a high isoionic point (pI) and LLPS is therefore promoted by salts and pH increases as they both reduce electrostatic repulsions. By contrast, full-length TDP-43 undergoes LSPS most favourably at its pI, with positive and negative salt dependences at lower and higher pH, respectively, depending on whether repulsive or attractive forces dominate, respectively.

Identifiants

pubmed: 38997630
doi: 10.1186/s11658-024-00615-4
pii: 10.1186/s11658-024-00615-4
doi:

Substances chimiques

DNA-Binding Proteins 0
TARDBP protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104

Subventions

Organisme : Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica
ID : AriSLA
Organisme : Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica
ID : project TDP-43-STRUCT
Organisme : Ministero dell'Università e della Ricerca
ID : PRIN Project 2020PBS5MJ
Organisme : Università degli studi di Firenze
ID : Fondi di Ateneo 2021

Informations de copyright

© 2024. The Author(s).

Références

Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative in-clusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006. https://doi.org/10.1016/j.bbrc.2006.10.093 .
doi: 10.1016/j.bbrc.2006.10.093 pubmed: 17207775
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006. https://doi.org/10.1126/science.1134108 .
doi: 10.1126/science.1134108 pubmed: 17023659
Neumann M, Mackenzie IRA. Review: neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019. https://doi.org/10.1111/nan.12526 .
doi: 10.1111/nan.12526 pubmed: 30907009
Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013. https://doi.org/10.1038/nrn3430 .
doi: 10.1038/nrn3430 pubmed: 23463272
Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White CL 3rd, Yu L, Schneider JA. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019. https://doi.org/10.1093/brain/awz099 .
doi: 10.1093/brain/awz099 pubmed: 31359039 pmcid: 6931389
Arseni D, Chen R, Murzin AG, Peak-Chew SY, Garringer HJ, Newell KL, Kametani F, Robinson AC, Vidal R, Ghetti B, Hasegawa M, Ryskeldi-Falcon B. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP. Nature. 2023. https://doi.org/10.1038/s41586-023-06405-w .
doi: 10.1038/s41586-023-06405-w pubmed: 38057661 pmcid: 10781619
Seyfried NT, Gozal YM, Dammer EB, Xia Q, Duong DM, Cheng D, Lah JJ, Levey AI, Peng J. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics. 2010. https://doi.org/10.1074/mcp.M800390-MCP200 .
doi: 10.1074/mcp.M800390-MCP200 pubmed: 20861518 pmcid: 3098581
Cohen TJ, Hwang AW, Restrepo CR, Yuan CX, Trojanowski JQ, Lee VM. An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun. 2015. https://doi.org/10.1038/ncomms6845 .
doi: 10.1038/ncomms6845 pubmed: 26690673
Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 2011. https://doi.org/10.1016/j.cell.2011.10.011 .
doi: 10.1016/j.cell.2011.10.011 pubmed: 22036560 pmcid: 3220614
Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009. https://doi.org/10.1212/WNL.0b013e3181b6bbbd .
doi: 10.1212/WNL.0b013e3181b6bbbd pubmed: 19738176 pmcid: 2739608
Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, McCluskey LF, Trojanowski JQ, Lee VM. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008. https://doi.org/10.2353/ajpath.2008.080003 .
doi: 10.2353/ajpath.2008.080003 pubmed: 18535185 pmcid: 2438296
Cohen TJ, Lee VMY, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011. https://doi.org/10.1016/j.molmed.2011.06.004 .
doi: 10.1016/j.molmed.2011.06.004 pubmed: 21783422 pmcid: 3202652
Halliday G, Bigio EH, Cairns NJ, Neumann M, Mackenzie IR, Mann DM. Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. 2012. https://doi.org/10.1007/s00401-012-1030-4 .
doi: 10.1007/s00401-012-1030-4 pubmed: 22878865 pmcid: 3445027
Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, Baralle FE, Damberger FF, Allain FH. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat Struct Mol Biol. 2013. https://doi.org/10.1038/nsmb.2698 .
doi: 10.1038/nsmb.2698 pubmed: 24240615
Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) Proteinopathies. J Biol Chem. 2016. https://doi.org/10.1074/jbc.M116.737726 .
doi: 10.1074/jbc.M116.737726 pubmed: 27445339 pmcid: 5016682
De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami AA, Mele A, Vidatic L, Kriz J, Julien JP, Apic G, Russell RB, Rogelj B, Cannon JR, Baralle M, Agosta F, Hecimovic S, Mazzini L, Buratti E, Munitic I. Emerging trends in the field of inflammation and proteinopathy in ALS/FTD spectrum disorder. Biomedicines. 2023;11:1599. https://doi.org/10.3390/biomedicines11061599 .
doi: 10.3390/biomedicines11061599 pubmed: 37371694 pmcid: 10295684
Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, Masliah E, Kaye J, Clark CM, Montine TJ, Lee VMY, Trojanowski JQ. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007. https://doi.org/10.1007/s00401-007-0261-2 .
doi: 10.1007/s00401-007-0261-2 pubmed: 17653732
Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol. 2007. https://doi.org/10.1002/ana.21154 .
doi: 10.1002/ana.21154 pubmed: 17469117 pmcid: 2677204
Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008. https://doi.org/10.1097/NEN.0b013e31818e8951 .
doi: 10.1097/NEN.0b013e31818e8951 pubmed: 19018245
Miguelez-Rodriguez A, Santos-Juanes J, Vicente-Etxenausia I, Perez de Heredia-Goñi K, Garcia B, Quiros LM, Lorente-Gea L, Guerra-Merino I, Aguirre JJ, Fernandez-Vega I. Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease. J Clin Pathol. 2018. https://doi.org/10.1136/jclinpath-2017-204794 .
doi: 10.1136/jclinpath-2017-204794 pubmed: 29097599
Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, Alosco ML, Solomon TM, Nowinski CJ, McHale L, Cormier KA, Kubilus CA, Martin BM, Murphy L, Baugh CM, Montenigro PH, Chaisson CE, Tripodis Y, Kowall NW, Weuve J, McClean MD, Cantu RC, Goldstein LE, Katz DI, Stern RA, Stein TD, McKee AC. Clinicopathological evaluation of chronic traumatic encephalopathy in players of american football. JAMA. 2017. https://doi.org/10.1001/jama.2017.8334 .
doi: 10.1001/jama.2017.8334 pubmed: 29260223 pmcid: 5807097
Conicella A, Zerze G, Mittal J, Fawzi N. ALS mutations disrupt phase separation mediated by α-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016. https://doi.org/10.1016/j.str.2016.07.007 .
doi: 10.1016/j.str.2016.07.007 pubmed: 27545621 pmcid: 5014597
Li HR, Chen TC, Hsiao CL, Shi L, Chou CY, Huang JR. The physical forces mediating self-association and phase-separation in the C-terminal domain of TDP-43. Biochem Biophys Acta Proteins Proteom. 2018. https://doi.org/10.1016/j.bbapap.2017.10.001 .
doi: 10.1016/j.bbapap.2017.10.001
Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, Laferriere F, Maniecka Z, Plückthun A, Mittl P, Paganetti P, Allain FHT, Polymenidou M. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017. https://doi.org/10.1038/s41467-017-00062-0 .
doi: 10.1038/s41467-017-00062-0 pubmed: 28663553 pmcid: 5491494
Wang A, Conicella AE, Schmidt HB, Martin EW, Rhoads SN, Reeb AN, Nourse A, Ramirez Montero D, Ryan VH, Rohatgi R, Shewmaker F, Naik MT, Mittag T, Ayala YM, Fawzi NL. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018. https://doi.org/10.15252/embj.201797452 .
doi: 10.15252/embj.201797452 pubmed: 30591555 pmcid: 6356068
Ayala YM, Zago P, D’Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008. https://doi.org/10.1242/jcs.038950 .
doi: 10.1242/jcs.038950 pubmed: 18957508
Shiina Y, Arima K, Tabunoki H, Satoh J. TDP-43 dimerizes in human cells in culture. Cell Mol Neurobiol. 2010. https://doi.org/10.1007/s10571-009-9489-9 .
doi: 10.1007/s10571-009-9489-9 pubmed: 20043239
Chang CK, Wu TH, Wu CY, Chiang MH, Toh EK, Hsu YC, Lin KF, Liao YH, Huang TH, Huang JJ. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012. https://doi.org/10.1016/j.bbrc.2012.07.071 .
doi: 10.1016/j.bbrc.2012.07.071 pubmed: 23266607 pmcid: 3415467
Zhang YJ, Caulfield T, Xu YF, Gendron TF, Hubbard J, Stetler C, Sasaguri H, Whitelaw EC, Cai S, Lee WC, Petrucelli L. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet. 2013. https://doi.org/10.1093/hmg/ddt166 .
doi: 10.1093/hmg/ddt166 pubmed: 24381306 pmcid: 3990172
Wang YT, Kuo PH, Chiang CH, Liang JR, Chen YR, Wang S, Shen JC, Yuan HS. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem. 2013. https://doi.org/10.1074/jbc.M112.438564 .
doi: 10.1074/jbc.M112.438564 pubmed: 24381168 pmcid: 3937661
Mompeán M, Romano V, Pantoja-Uceda D, Stuani C, Baralle FE, Buratti E, Laurents DV. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 2016. https://doi.org/10.1111/febs.13651 .
doi: 10.1111/febs.13651 pubmed: 26756435
Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009. https://doi.org/10.1016/j.brainres.2008.10.021 .
doi: 10.1016/j.brainres.2008.10.021 pubmed: 19619516
Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, Ratti A. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009. https://doi.org/10.1111/j.1471-4159.2009.06383.x .
doi: 10.1111/j.1471-4159.2009.06383.x pubmed: 19765185
Dammer EB, Fallini C, Gozal YM, Duong DM, Rossoll W, Xu P, Lah JJ, Levey AI, Peng J, Bassell GJ, Seyfried NT. Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS ONE. 2012. https://doi.org/10.1371/journal.pone.0038658 .
doi: 10.1371/journal.pone.0038658 pubmed: 22761693 pmcid: 3380899
Nishimoto Y, Nakagawa S, Hirose T, Okano HJ, Takao M, Shibata S, Suyama S, Kuwako KI, Imai T, Murayama S. The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. Mol Brain. 2013. https://doi.org/10.1186/1756-6606-6-31 .
doi: 10.1186/1756-6606-6-31 pubmed: 23835137 pmcid: 3729541
Udan-Johns M, Bengoechea R, Bell S, Shao J, Diamond MI, True HL, Weihl CC, Baloh RH. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genetics. 2014. https://doi.org/10.1093/hmg/ddt408 .
doi: 10.1093/hmg/ddt408
Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, Da Cruz S, Cleveland D. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019. https://doi.org/10.1016/j.neuron.2019.02.038 .
doi: 10.1016/j.neuron.2019.02.038 pubmed: 30853299 pmcid: 6548321
Yu H, Lu S, Gasior K, Singh D, Vazquez-Sanchez S, Tapia O, Toprani D, Beccari MS, Yates JR 3rd, Da Cruz S, Newby JM, Lafarga M, Gladfelter AS, Villa E, Cleveland DW. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021. https://doi.org/10.1126/science.abb4309 .
doi: 10.1126/science.abb4309 pubmed: 34840353 pmcid: 9017870
Carey JL, Guo L. Liquid-liquid phase separation of TDP-43 and FUS in physiology and pathology of neurodegenerative diseases. Front Mol Biosci. 2022;2(9): 826719. https://doi.org/10.3389/fmolb.2022.826719 .
doi: 10.3389/fmolb.2022.826719
Chen Y, Cohen T. Aggregation of the nucleic acid–binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019. https://doi.org/10.1074/jbc.RA118.006351 .
doi: 10.1074/jbc.RA118.006351 pubmed: 31914415 pmcid: 7029124
Hans F, Glasebach H, Kahle P. Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. J Biol Chem. 2020. https://doi.org/10.1074/jbc.RA119.010617 .
doi: 10.1074/jbc.RA119.010617 pubmed: 31780563
Ratti A, Gumina V, Lenzi P, Bossolasco P, Fulceri F, Volpe C, Bardelli D, Pregnolato F, Maraschi A, Fornai F, Silani V, Colombrita C. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol Dis. 2020. https://doi.org/10.1016/j.nbd.2020.105051 .
doi: 10.1016/j.nbd.2020.105051 pubmed: 32827688
Cascella R, Bigi A, Riffert DG, Gagliani MC, Ermini E, Moretti M, Cortese K, Cecchi C, Chiti F. A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Sci Adv. 2022. https://doi.org/10.1126/sciadv.abm6376 .
doi: 10.1126/sciadv.abm6376 pubmed: 35895809 pmcid: 9328675
Choi KJ, Tsoi PS, Moosa MM, Paulucci-Holthauzen A, Liao SJ, Ferreon JC, Ferreon ACM. A chemical chaperone decouples TDP-43 disordered domain phase separation from fibrillation. Biochemistry. 2018. https://doi.org/10.1021/acs.biochem.8b01051 .
doi: 10.1021/acs.biochem.8b01051 pubmed: 30520303
Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, Surewicz WK. The role of liquid–liquid phase separation in aggregation of the TDP-43 low-complexity domain. J Biol Chem. 2019. https://doi.org/10.1074/jbc.RA118.007222 .
doi: 10.1074/jbc.RA118.007222 pubmed: 30814253 pmcid: 6484124
Pakravan D, Michiels E, Bratek-Skicki A, De Decker M, Van Lindt J, Alsteens D, Derclaye S, Van Damme P, Schymkowitz J, Rousseau F, Tompa P, Van Den Bosch L. Liquid-liquid phase separation enhances TDP-43 LCD aggregation but delays seeded aggregation. Biomolecules. 2021. https://doi.org/10.3390/biom11040548 .
doi: 10.3390/biom11040548 pubmed: 33917983 pmcid: 8068378
Garg DK, Bhat R. Modulation of assembly of TDP-43 low-complexity domain by heparin: From droplets to amyloid fibrils. Biophys J. 2022. https://doi.org/10.1016/j.bpj.2022.05.042 .
doi: 10.1016/j.bpj.2022.05.042 pubmed: 35644946 pmcid: 9300664
Molliex A, Temirov J, Le J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015. https://doi.org/10.1016/j.cell.2015.09.015 .
doi: 10.1016/j.cell.2015.09.015 pubmed: 26406374 pmcid: 5149108
Sun Y, Medina Cruz A, Hadley KC, Galant NJ, Law R, Vernon RM, Morris VK, Robertson J, Chakrabartty A. Physiologically important electrolytes as regulators of TDP-43 aggregation and droplet-phase behavior. Biochemistry. 2019. https://doi.org/10.1021/acs.biochem.8b00842 .
doi: 10.1021/acs.biochem.8b00842 pubmed: 31799836
Krainer G, Welsh TJ, Joseph JA, Espinosa JR, Wittmann S, de Csilléry E, Sridhar A, Toprakcioglu Z, Gudiškytė G, Czekalska MA, Arter WE, Guillén-Boixet J, Franzmann TM, Qamar S, George-Hyslop PS, Hyman AA, Collepardo-Guevara R, Alberti S, Knowles TPJ. Reentrant liquid condensate phase of proteins is stabilized by hydrophobic and non-ionic interactions. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-21181-9 .
doi: 10.1038/s41467-021-21181-9 pubmed: 34650037 pmcid: 8516981
Gruijs Silva LA, Simonetti F, Hutten S, Riemenschneider H, Sternburg EL, Pietrek LM, Gebel J, Dötsch V, Edbauer D, Hummer G, Stelzl LS, Dormann D. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO J. 2022. https://doi.org/10.15252/embj.2021108443 .
doi: 10.15252/embj.2021108443
Staderini T, Bigi A, Mongiello D, Chiti F. Biophysical characterization of full length TAR DNA-binding protein (TDP-43) phase separation. Protein Sci. 2022. https://doi.org/10.1002/pro.4509 .
doi: 10.1002/pro.4509 pubmed: 36371546 pmcid: 9703588
McGurk L, Gomes E, Guo L, Mojsilovic-Petrovic J, Tran V, Kalb RG, Shorter J, Bonini NM. Poly(ADP-Ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol Cell. 2018. https://doi.org/10.1016/j.molcel.2018.07.002 .
doi: 10.1016/j.molcel.2018.07.002 pubmed: 30100264 pmcid: 6128762
Carter GC, Hsiung CH, Simpson L, Yang H, Zhang X. N-terminal domain of TDP43 enhances liquid-liquid phase separation of globular proteins. J Mol Biol. 2021. https://doi.org/10.1016/j.jmb.2021.166948 .
doi: 10.1016/j.jmb.2021.166948 pubmed: 33744316 pmcid: 8094807
Wright GSA, Watanabe TF, Amporndanai K, Plotkin SS, Cashman NR, Antonyuk SV, Hasnain SS. Purification and structural characterization of aggregation-prone human TDP-43 involved in neurodegenerative diseases. iScience. 2020. https://doi.org/10.1016/j.isci.2020.101159 .
doi: 10.1016/j.isci.2020.101159 pubmed: 33134899 pmcid: 7588868
Ballou DP, Benore M, Ninfa AJ. Fundamental laboratory approaches for biochemistry and biotechnology. 2nd ed. Hoboken: Wiley; 2008. p. 127–9.
Meyer RK, Lustig A, Oesch B, Fatzer R, Zurbriggen A, Vandevelde M. A monomer-dimer equilibrium of a cellular prion protein (PrPC) not observed with recombinant PrP. J Biol Chem. 2000. https://doi.org/10.1074/jbc.M007114200 .
doi: 10.1074/jbc.M007114200 pubmed: 10753907
Beloti LL, Costa BZ, Toledo MA, Santos CA, Crucello A, Fávaro MT, Santiago AS, Mendes JS, Marsaioli AJ, Souza AP. A novel and enantioselective epoxide hydrolase from Aspergillus brasiliensis CCT 1435: purification and characterization. Protein Expr Purif. 2013. https://doi.org/10.1016/j.pep.2013.08.001 .
doi: 10.1016/j.pep.2013.08.001 pubmed: 23973866
Rastogi N, Zarin S, Alam A, Konduru GV, Manjunath P, Mishra A, Kumar S, Nagarajaram HA, Hasnain SE, Ehtesham NZ. Structural and biophysical properties of therapeutically important proteins Rv1509 and Rv2231A of Mycobacterium tuberculosis. Int J Biol Macromol. 2023. https://doi.org/10.1016/j.ijbiomac.2023.125455 .
doi: 10.1016/j.ijbiomac.2023.125455 pubmed: 37660858
Vivoli Vega M, Nigro A, Luti S, Capitini C, Fani G, Gonnelli L, Boscaro F, Chiti F. Isolation and characterization of soluble human full-length TDP-43 associated with neurodegeneration. FASEB J. 2019. https://doi.org/10.1096/fj.201900474R .
doi: 10.1096/fj.201900474R pubmed: 31287959
Zacco E, Graña-Montes R, Martin SR, de Groot NS, Alfano C, Tartaglia GG, Pastore A. RNA as a key factor in driving or preventing self-assembly of the TAR DNA-binding protein 43. J Mol Biol. 2019. https://doi.org/10.1016/j.jmb.2019.01.028 .
doi: 10.1016/j.jmb.2019.01.028 pubmed: 30742796 pmcid: 6461199
Kuo PH, Doudeva LG, Wang YT, Shen CK, Yuan HS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009. https://doi.org/10.1093/nar/gkp013 .
doi: 10.1093/nar/gkp013 pubmed: 20034954 pmcid: 2847232
Chiang CH, Grauffel C, Wu LS, Kuo PH, Doudeva LG, Lim C, Shen CK, Yuan HS. Structural analysis of disease-related TDP-43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci Rep. 2016. https://doi.org/10.1038/srep21581 .
doi: 10.1038/srep21581 pubmed: 28008953 pmcid: 5180243
Lackowicz JR. Principles of fluorescence spectroscopy. New York: Springer; 2006.
doi: 10.1007/978-0-387-46312-4
Comert F, Dubin PL. Liquid-liquid and liquid-solid phase sepa- ration in protein-polyelectrolyte systems. Adv Colloid Interface Sci. 2017. https://doi.org/10.1016/j.cis.2016.08.005 .
doi: 10.1016/j.cis.2016.08.005 pubmed: 27773339
Gopal PP, Nirschl JJ, Klinman E, Holzbaur EL. Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. Proc Natl Acad Sci U S A. 2017. https://doi.org/10.1073/pnas.1614462114 .
doi: 10.1073/pnas.1614462114 pubmed: 28265061 pmcid: 5373408
Soldi G, Bemporad F, Torrassa S, Relini A, Ramazzotti M, Taddei N, Chiti F. Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys J. 2005. https://doi.org/10.1529/biophysj.105.067538 .
doi: 10.1529/biophysj.105.067538 pubmed: 16169977 pmcid: 1366988
De Simone A, Dhulesia A, Soldi G, Vendruscolo M, Hsu ST, Chiti F, Dobson CM. Experimental free energy surfaces reveal the mechanisms of maintenance of protein solubility. Proc Natl Acad Sci U S A. 2011. https://doi.org/10.1073/pnas.1112197108 .
doi: 10.1073/pnas.1112197108 pubmed: 22160682 pmcid: 3248487
Capitini C, Conti S, Perni M, Guidi F, Cascella R, De Poli A, Penco A, Relini A, Cecchi C, Chiti F. TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLoS ONE. 2014;9(1): e86720. https://doi.org/10.1371/journal.pone.0086720 .
doi: 10.1371/journal.pone.0086720 pubmed: 24497973 pmcid: 3907574
Gu J, Wang C, Hu R, Li Y, Zhang S, Sun Y, Wang Q, Li D, Fang Y, Liu C. Hsp70 chaperones TDP-43 in dynamic, liquid-like phase and prevents it from amyloid aggregation. Cell Res. 2021. https://doi.org/10.1038/s41422-021-00526-5 .
doi: 10.1038/s41422-021-00526-5 pubmed: 34837059 pmcid: 8617373
Lu S, Hu J, Arogundade OA, Goginashvili A, Vazquez-Sanchez S, Diedrich JK, Gu J, Blum J, Oung S, Ye Q, Yu H, Ravits J, Liu C, Yates JR 3rd, Cleveland DW. Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Nat Cell Biol. 2022. https://doi.org/10.1038/s41556-022-00988-8 .
doi: 10.1038/s41556-022-00988-8 pubmed: 36266488 pmcid: 9872726
Maharana S, Wang J, Papadopoulos DK, Richter D, Pozniakovsky A, Poser I, Bickle M, Rizk S, Guillén-Boixet J, Franzmann TM, Jahnel M, Marrone L, Chang YT, Sterneckert J, Tomancak P, Hyman AA, Alberti S. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018. https://doi.org/10.1126/science.aar7366 .
doi: 10.1126/science.aar7366 pubmed: 29650702 pmcid: 6091854
Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, Castanedes-Casey M, Kurti A, Stankowski JN, Disney MD, Rothstein JD, Dickson DW, Fryer JD, Zhang YJ, Petrucelli L. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener. 2019. https://doi.org/10.1186/s13024-019-0310-z .
doi: 10.1186/s13024-019-0310-z pubmed: 30767771 pmcid: 6377782
Wang C, Duan Y, Duan G, Wang Q, Zhang K, Deng X, Qian B, Gu J, Ma Z, Zhang S, Guo L, Liu C, Fang Y. Stress induces dynamic, cytotoxicity-antagonizing TDP-43 nuclear bodies via paraspeckle LncRNA NEAT1-mediated liquid-liquid phase separation. Mol Cell. 2020. https://doi.org/10.1016/j.molcel.2020.06.019 .
doi: 10.1016/j.molcel.2020.06.019 pubmed: 33385326 pmcid: 7897279

Auteurs

Tommaso Staderini (T)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.
Department of Chemistry "Ugo Schiff", University of Florence, 50019, Florence, Italy.
Magnetic Resonance Center (CERM), University of Florence, Sesto Fiorentino, 50019, Florence, Italy.

Alessandra Bigi (A)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.

Clément Lagrève (C)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.
Chimie ParisTech-PSL, École Nationale Supérieur de Chimie de Paris, 11 rue Pierre et Marie Curie, 75231, Paris, France.

Isabella Marzi (I)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.

Francesco Bemporad (F)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.

Fabrizio Chiti (F)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy. fabrizio.chiti@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH